Status:
COMPLETED
Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)
Lead Sponsor:
University Hospital Muenster
Collaborating Sponsors:
Deutsche Krebshilfe e.V., Bonn (Germany)
German Federal Ministry of Education and Research
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
The study in patients with primary and secondary AML and high-risk MDS uses a risk-stratified, randomized design to evaluate the role of high-dose araC in induction, of G-CSF priming, and of autologou...
Detailed Description
The present study by the German AML Cooperative Group has been designed in order to investigate the effects of AML typical therapeutic strategies for AML and related diseases. Thus, the entry criteria...
Eligibility Criteria
Inclusion
- Acute myeloid leukemia (de-novo AML, secondary AML, high-risk MDS)
- Age 16 - no upper age limit
- Written informed consent
Exclusion
- Severe comorbidity
- Presence of other malignancy
- Prior anti-leukemic treatment
- Pregnancy
- Severe psychiatric disorder or other circumstances which may compromise cooperation of the patients
Key Trial Info
Start Date :
June 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT00266136
Start Date
June 1 1999
End Date
October 1 2012
Last Update
October 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology
Münster, Germany, 48129